|
Originally published In Press as doi:10.1074/jbc.M005901200 on July 20, 2000
J. Biol. Chem., Vol. 275, Issue 40, 31134-31144, October 6, 2000
The Identification of a Nonclassical Cadherin Expressed during B
Cell Development and Its Interaction with Surrogate Light Chain*
Kazuo
Ohnishi §,
Takeyuki
Shimizu ,
Hajime
Karasuyama¶, and
Fritz
Melchers
From the Basel Institute for Immunology,
Grenzacherstrasse 487, CH-4005 Basel, Switzerland and the
¶ Department of Immunology, The Tokyo Metropolitan Institute of
Medical Science, Tokyo 113-8613, Japan
Received for publication, July 5, 2000
 |
ABSTRACT |
A 130-kDa glycoprotein (p130) has been found to
be associated with surrogate light chain on pro- and pre-B I cells.
Using peptide sequences obtained from purified p130 we have cloned its gene. The gene encodes a typical cadherin type 1 membrane protein with
six extracellular cadherin domains (one pseudo domain) but lacking the
catenin-binding site in its cytoplasmic part. Even without this
catenin-binding site, p130 mediates
Ca2+-dependent homotypic adhesion of
cells. The interaction of p130 with surrogate light chain is confirmed
by co-transfection and co-immunoprecipitation experiments. The
expression of p130 is biphasic during the B cell development. Reverse
transcriptase-polymerase chain reaction and flow cytometric
analyses revealed that it is expressed on
B220+c-Kit+ pro-B and pre-B-I cells as
well as on B220+CD25 IgM+ immature
and mature B cells but not on B220+CD25+
pre-B-II cells. It is also expressed in fetal liver, at low levels in
myeloid cells, and strongly in intestinal epithelial cells. In the
spleen, p130-expressing cells are mainly localized in the marginal
zone. We call this B lineage-, intestine-, liver- and leukocyte-expressed gene BILL-cadherin. The possible functions of
BILL-cadherin in B cell development are discussed.
 |
INTRODUCTION |
In adult mice, antibody-producing B cells develop from
hematopoietic stem cells in bone marrow. The early development of B cell progenitors, the timing and the order of the Ig gene
rearrangements, and the subsequent positive and negative selection of
the newly emerging B cells are regulated by a programmed pattern of
gene expression and by ordered interactions of different stages of B
lineage cells with the bone marrow microenvironment (see reviews in
Refs. 1-5).
Several key molecules play crucial roles in this cellular development.
The development of early precursor B cells (pro/pre-B-I) in bone marrow
requires attachment to stromal cells, which involves interactions with
Flk-2 and c-Kit on B lineage precursors and their corresponding
ligands on stroma cells (6). Interaction of progenitor B cells with the
stromal cells induces the production of IL-7 by stromal cells
(7). The IL-7 acts via IL-7 receptor on pro- and pre-B cells to allow
their survival and proliferation, in concert with other interactions
between the two lineage of cells (8-10). In the adhesive pro/pre-B
cell-stromal cell interactions, CD44 (Pgp-1), a receptor for
hyaluronate, and the integrin VLA-4 (CD49d/CD29) are involved (11).
In the bone marrow, B cell precursors move from the peripheral region
near the surrounding bone to the central sinusoids as they mature and
differentiate (4, 12). The chemokine stroma cell-derived factor-1 might
play a role in this migration (13). During this movement,
differentiating B cells are thought to interact with various
types of stromal cells. However, most of the molecular mechanisms
responsible for these vectorial and sequential interactions remain to
be elucidated.
Other migrations occur during the generation of the peripheral B cell
compartments. Immature B cells exit the bone marrow and enter the
spleen through the central artery, the arteriole, and finally the
marginal sinuses to become localized in the marginal zone and
follicular areas (14-16). Again, almost nothing is known about the
genes and the molecules that control these cellular migrations and selections.
A 130-kDa glycoprotein, p130, has been found associated with surrogate
light chain (SL chain)1 on
pro-B and pre-B-I cells, which either have all Ig gene loci in germline
configuration or are DHJH rearranged and hence
do not yet express µ heavy chains. The SL chain is composed of the Vpre-B1 and 5 proteins. Together with µ heavy chains, it can form
pre-B cell receptors that become expressed in and on large VHDHJH rearranged pre-B cells (17).
Pre-B cell receptors signal clonal expansion of these so-called large
pre-B-II cells and are thought to be also involved in allelic exclusion
of the H chain locus (9, 17-20).
In pro-B, pre-B-I, and large pre-B-II cells, the majority of SL chain
molecules are localized in the cytoplasm. However, small amounts are
also found on the surface (21, 22). Because pro-B and pre-B-I cells do
not yet express µ heavy chains, other molecules might be associated
with SL chain in these early B lineage cells to allow surface
deposition (22). A complex of glycoproteins (of 200, 130, and 105 kDa
and several proteins between 35 and 65 kDa) have been found associated
with SL chain on the surface of mouse pro-B and pre-B-I cell lines (23,
24). A similar complex is also found on human pro-B cells in which the
major component is a 125-kDa protein (25).
Here we report the purification and partial amino acid sequence
determination of the p130 molecule associated with SL chain. This, in
turn, then allows the cloning of the gene encoding p130, which is found
to be a new member of the cadherin family. We show that the expression
of this nonclassic cadherin molecule is biphasic during the B cell
ontogeny and that the expression in SL chain-producing cells allows the
surface deposition of SL chain-p130 complexes.
 |
EXPERIMENTAL PROCEDURES |
Animals and Cell Lines--
Female BALB/c and C57BL/6 mice
(3-5-weeks old) were purchased from Biological Research Laboratories,
Ltd. (Fuellinsdorf, Switzerland). 38B9 mouse pro-B cell line and
most of the cell lines used here were described previously (23). In
addition, murine leukemia virus transformed
µ+ cell lines from BALB/c mice Ig6.3
(26), the immature T cell lines SCFET27F, and B6.2.16.BU (27) were
used. All cell lines were maintained in Iscove's modified Dulbecco's
medium supplemented with 10% fetal calf serum, 100 units/ml
of penicillin-streptomycin, 2 mM
L-glutamine, and 5 × 10 5 M
2-mercaptoethanol.
Antibodies--
Rat monoclonal antibodies used were LM34 and
LM33 specific for mouse 5 (23), M41 specific for murine µ heavy
chain (28), 9EG7 (anti- 1-integrin, kindly provided by
Dr. Beat Imhof), and M1/9.3.4 (anti-B220 (29)). All other monoclonal
antibodies were purchased from Pharmigen. The polyclonal
anti- 1-integrin was kindly provided by B. Imhof.
Immunoprecipitation Analysis--
Isotope labeling of the cells,
lysis, and subsequent immunoprecipitations were performed as described
previously (30). Briefly, 125I-labeled cells (5 × 107) were lysed with 1 ml of ice-cold lysis buffer
containing 1% Nonidet P-40, 50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 5 mM EDTA, 10 mM
iodoacetamide, and protease inhibitors. After a centrifugation, the
supernatant was precleared with rabbit normal Ig-Sepharose conjugate
and then immunoprecipitated with 20 µg of each antibody immobilized
to Sepharose 4B. Samples were washed three times and analyzed on the
one-dimensional and/or two-dimensional gel electrophoresis as
described previously (30).
Purification of p130--
About 100 pmol (10 µg) of p130 was
purified from 5 × 1011 of 38B9 (pro-B) cells by
several batches of the purification steps as described below. 38B9
(2.5 × 1010) cells were lysed with 250 ml of Nonidet
P-40 lysis buffer (1% Nonidet P-40, 50 mM Tris-HCl (pH
7.5), 300 mM NaCl, 5 mM EDTA, 10 mM
iodoacetamide, 20 mM -aminocaproic acid, 1 µg/ml
antipain, 10 µg/ml benzamide, 1 µg/ml chymostatin, 1 mM
phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 2.5 units/ml
aprotinin, and 1 µg/ml pepstatin) on ice for 10 min. As the tracer
for 5-associated p130, anti- 5 immunoprecipitate from
125I-labeled 38B9 cells were added to the final batch of
the purification. The lysate was then cleared by centrifugation
(105,000 × g). The supernatant was incubated with
1-ml gel of RCA120-Sepharose (Ricinus communis
agglutinin, Sigma L-2390) at 4 °C overnight. The
RCA120-Sepharose bound samples were washed three times with
Nonidet P-40 lysis buffer containing 0.5 M NaCl and eluted
with 0.5 M galactose/2 M NaCl in Nonidet P-40
lysis buffer at 4 °C for 4 h. The eluate was stored at
20 °C as RCA120 fraction.
The RCA120 fractions from 5 × 1011 cells
were pooled, and the proteins were precipitated by the method of Wessel
and Flugge (31). The proteins were then solubilized with the buffer A
(8 M urea, 50 mM Tris-HCl (pH 7.5), 0.1%
CHAPS, 0.5 mM dithiothreitol, and 2 mM EDTA).
After a passage through a 0.2-µm filter, the sample was loaded on
Mono-Q column (Amersham Pharmacia Biotech) and eluted in a gradient of
NaCl (0-1.0 M NaCl in buffer A). As the fractions corresponding to 0.5-0.6 M NaCl contained p130, these
fractions were pooled, dialyzed against 10 mM
(NH4)2CO3, and lyophilized.
The lyophilized sample was dissolved with the sample buffer of NEPHGE,
cleared by a centrifugation, and subjected to NEPHGE/SDS-PAGE as
described previously (30). After the electrophoresis, proteins were
transferred to a polyvinylidene difluoride membrane and stained with
Ponseau S. The spot corresponding to p130 was identified with
125I-labeled p130 protein, which was immuno-co-precipitated
with anti- 5 antibody, cut out, and analyzed as described below.
N-terminal Protein Sequence Analysis--
The 130-kDa protein
containing polyvinylidene difluoride membrane, which separated as
above, was rendered to the digestion with lysine-C. The digestion,
separation on HPLC, MALD-MS of the HPLC fractions, and N-terminal amino
acid sequencing of the peptides were performed by Dr. William S. Lane's Laboratory (Harvard microchemistry facility) and the facility
in our Institute.
PCR and cDNA Library Screening--
The design of the
gene-specific oligonucleotide PCR primers (p130pk37sens,
5'-AARATYGTBCARGGNGA-3'; p130pk37anti, 5'-GCRTTIGTIGTDGGRTCNGT-3') was
based on the N-terminal six amino acids and seven C-terminal amino
acids of peak-37 peptide ((K)IVQGDTEXRLEVVTDPTTNA)
using a preferred codon usage in the rabbit. The PCRs were "hot
started" and subjected to the thermal cycles as follows: one cycle of
10 s at 96 °C, 30 cycles of (5 s at 96 °C, 15 s at
55 °C, and 60 s at 72 °C), and one cycle at 72 °C for 10 min using OmniGene thermal cycler (HYBAID Limited, Middlesex, UK).
PCR products were size fractionated on a 3% agarose gel and
transferred to nylon filters (Zeta-Probe membrane, Bio-Rad). PCR products that hybridized to the 32P-end-labeled internal,
gene-specific oligonucleotide probes p130pk37 m(5'-ACNGARIIINGIYTIGARTIGTIAC-3') were identified and subcloned into
the pCRTMII vector using the TA CloningTM
system (Invitrogen Corp.).
From the deduced sequence, the primers p130pk37-3'
(5'-AAGATTGTACAGGGAGA-3') and p130pk37-5' (5'-TGGGATCTGTGACAAC-3')
were designed for MarathonTM cDNA amplification method
(CLONTECH Laboratories, Inc., Palo Alto,
California), and RACE-PCR (32) was performed according to the protocol
from the company. The amplified products were size fractionated on a
1.2% agarose gel and subcloned into the pCRTMII vector. To
obtain longer fragment, p130RACE-5' (5'-AATAACTCACAGTCAGGCCTTCAGGAT-3') and p130RACE-3' (5'- ACACAGACATCGGATCCACCATCCTAA-3') were used in place of p130pk37-5' and p130pk37-3', respectively, and
ExpandTM High Fidelity (Roche Molecular Biochemicals) was
used. The amplified fragments were cloned into pCR-ScriptTM
(Stratagene, La Jolla, CA) and sequenced as described below.
In parallel, the gt10 38B9 cDNA library was screened by the
plaque-lift method with a 32P-labeled 0.2-kilobase
PCR product (Hpk37) amplified using Hpk37s (5'-GACACAGCCATCGGATC-3') and Hpk37a (5'-TGGGATCTGTGACAAC-3') as
the primers after the method described in Ref. 33. cDNA clones were
recovered from positive gt10 plaques and cloned into pBluescript II
SK . DNA sequence analysis of cDNA inserts were
performed by the Taq DyeDeoxyTM Terminator Cycle
sequencing method using an automated sequencer (model 373A, Applied
Biosystems, Inc., Foster City, CA).
Northern Blot and RT-PCR Analysis--
Total RNA was isolated
from various mouse tissues and from various cell lines by a
modification of phenol and guanidine isothiocyanate method described by
Chomczynski and Sacchi (34). Total RNA (20 µg) was electrophoresed
through 1% agarose gels containing 0.67% formaldehyde, transferred to
nylon filters (Zeta-Probe membrane, Bio-Rad), prehybridized, and
hybridized with 32P-labeled Hpk37 fragment for 24 h at
68 °C. Filters were washed in 2× SSC containing 0.02% SDS for 30 min at room temperature and then 0.1× SSC containing 0.1% SDS for 40 min at 50 °C. The filters were then autoradiographed on a film or
analyzed by a PhosphoImager (Molecular Dynamics).
Semi-quantitative RT-PCR on cell lines and sorted cells was performed
basically as described previously (35). Briefly, total RNA was isolated
from sorted 3 × 103 cells and reverse transcribed
using Superscript II reverse transcriptase (Life Technologies, Inc.).
RT-PCR assays were carried out with the series of template dilutions to
obtain a linear correlation between input template and PCR
product. The primer pairs used are as follows; p130,
5'-GCACTTCATTCACATCCGTCA-3' and 5'-GCTAACAACATCAACAGTATTTTG-3'; HPRT,
5'-GCTGGTGAAAAGGACCTCT-3' and 5'-CACAGGACTAGAACACCTGC-3'; 5,
5'-GAGATCTAGACTGCAAGTGAGGCTAGAG-3' and 5'-CTTGGGCTGACCTAGGATTG-3'. The PCR products are examined by Southern blot using the probe as
described above (p130) and previously (HPRT, 5 (35)). The hybridization signals were quantitated by the PhosphoImager equipped with ImageQuant software (Molecular Dynamics). The relative contents of
the messages in each cell and tissue were normalized by HPRT and
estimated from the linear region of the template dilution versus PCR product plot.
Isolation of p130 Transfected Cell Lines--
X63.Ag8.653 cell
line transfected with Vpre-B1 and 5 cDNA, X63/Vpre-B1/ 5, was
described previously (36) and maintained in 1 mg/ml hygromycin B (Roche
Molecular Biochemicals). Supertransfection of X63.Ag8.653 was carried
out as follows. Full-length cDNA of p130 was cloned into
XhoI site of retrovirus vector, LXSP. LXSP is a derivative
of LXSN (37), in which puromycin resistant gene was introduced in place
of neomycin resistant gene. LXSP/p130 was linearized by PvuI
cut and transfected into packaging cell line, gp+E- (38) by
DOTAP method
(N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate, Roche Molecular Biochemicals). After the selection of LXSP/p130 transfected gp+E-86 cells with 3 µg/ml puromycin, the
cells were cultured to confluent monolayer, -irradiated with 3000R
and the X63/Vpre-B1/ 5 cells were overlaid for overnight without
addition of puromycin. After the selection with 3-6 µg/ml puromycin,
the transfectants were cloned by limiting dilution.
Culture, transfection, and cloning of Drosophila Schneider
cells (SL-3) were performed according to Ref. 39. Briefly, p130 cDNA was cloned into pRmHa-3 (40) under the control of
metallothionein promoter and transfected into SL-3 cells with
phshs-puro (containing the puromycin resistance gene under the heat
shock promoter; a kind gift of K. Karjalainen, Basel Institute
for Immunology) using Lipofectin (Life Technologies, Inc.). After the
selection with 6 µg/ml puromycin, cells were tested for the
aggregation according to Berndorff et al. (41).
 |
RESULTS |
Purification and Amino Acid Sequencing of p130--
The surrogate
light chain is expressed on the cell surface of pro-B cells in mouse
bone marrow as well as pro-B cell lines such as 38B9 and 63-12 in the
absence of µ heavy chains (23). Cell surface iodination and
subsequent immunoprecipitation with anti- 5 or anti-Vpre-B1 antibody
revealed that 130- and 35-65-kDa molecules are the main components
that appear associated in a complex with SL chain (Fig.
1A). The two-dimensional gel
patterns show that p130 is a slightly acidic protein (pI = ~5.8), whereas the 33-65-kDa molecules are relatively neutral
(pI = ~5-7). The 130- and 35-65-kDa molecules are
glycoproteins. Hence, deglycosylation of the complex with PNGase F gave
rise to a 100-kDa protein and several 30-45-kDa proteins of slightly
different neutral pIs. The differential SDS-PAGE analysis under
nonreducing versus reducing conditions revealed no
differences in migration of the 100- and 30-45-kDa deglycosylated
components, indicating that they are not disulfide-linked (23). The
association of the glycosylated 35-65-kDa molecules appears to be more
ubiquitous because they are also co-precipitated, for example, in
complexes with anti-B220 mAb in which SL chain and p130 are not found
(Fig. 1B). Therefore, we chose the 130-kDa molecule
(subsequently referred to as p130) as the most probable protein partner
of SL chain on pro-B and pre-B-I cells.

View larger version (86K):
[in this window]
[in a new window]
|
Fig. 1.
The surrogate light chain containing complex
on pro-B cell line and the purification of the 130-kDa component.
A, murine leukemia virus -transformed pro-B cell line, 38B9,
was surface iodinated with 125I, lysed by Nonidet P-40
(1%), and immunoprecipitated with anti- 5 (LM34) antibody. The
immunoprecipitates were analyzed by two-dimensional gel electrophoresis
(NEPHGE/SDS-PAGE; the pH range of the first dimension is about 4-10,
and the second dimension is 6-20% gradient gel). The positions of the
130-kDa component (p130), 5, and Vpre-B1 are indicated.
B, the comparison of immunoprecipitates from 38B9 pro-B cell
line. After the surface iodination and the lysis with 1% Nonidet P-40,
proteins were immunoprecipitated with rat normal-Ig, anti- 5 (LM34),
anti-CD16/CD32 (2.4G2), anti-B220 (CD45, M1/9.3.4),
anti- 1-integrin (polyclonal), and
anti- 4-integrin (polyclonal). The samples were analyzed
on SDS-PAGE (6-20% gradient gel). The positions of p130, 5, and
Vpre-B1 are indicated at the right. C, The
partially purified p130 fraction. An aliquot from the p130 containing
fraction of HPLC (Mono-Q, to which RCA120-bound proteins
from 38B9 was loaded) was mixed with the tracer
(125I-labeled LM34 immunoprecipitates) and analyzed on
NEPHGE/SDS-PAGE. The proteins were detected by silver stain. The
positions of p130 and Vpre-B1 were located by the
125I-labeled tracer. The large spot of p130 was cut out and
analyzed further. D, the elution profile of the reverse
phase HPLC on which lysine-C-digested proteins from the p130 spot were
loaded. The arbitrary chosen peaks were analyzed by MALD-MS to obtain
the peptide of unknown mass. One of the peptides with unknown mass is
indicated (pk37). E, the MALD-MS profile of peak
37. This fragment gave the longest unknown sequence as
IVQGDTEXRLEVVTDPTTNA.
|
|
To purify sufficient quantities of p130 that could be entered into an
amino acid sequence analysis, 5 × 1011 38B9 pro-B
cells were lysed with Nonidet P-40 lysis buffer and absorbed with
ricin-lectin (RCA120-agarose). Bound material was eluted
with 0.5 M galactose, then loaded on a Mono-Q column, and eluted with an NaCl gradient. p130 was eluted around 0.5 M
NaCl (for details, see "Experimental Procedures"). The purity of
the eluted fraction containing p130 was estimated to be about 50%. As
revealed by a comparison of the two-dimensional NEPHGE/SDS-PAGE gel of
the fraction where protein was detected by silver staining (Fig.
1C), with the spot corresponding to p130 as it could be identified by co-electrophoresed 125I-labeled p130 tracer
protein, which is immunoprecipitated with anti- 5 from the iodinated
same cell line. The p130 spot appeared fairly isolated from other spots
on the gel. Consequently it was blotted to a polyvinylidene difluoride
membrane, subjected to lysine-C digestion, and the resulting peptides
were separated on reverse phase HPLC (Fig. 1D). The amino
acid sequences of some of the isolated peaks were determined (Table
I). It became evident from this analysis
that the p130 spot represented a mixture of 1-integrin
and an unknown, p130 protein.
View this table:
[in this window]
[in a new window]
|
Table I
Amino acid sequences obtained from partially purified p130
p130 corresponding spot on two-dimensional gel was excised, treated
with Lys-C, separated on reverse phase HPLC, and sequenced by Edman
Degradation (see "Experimental Procedures" for the details). All
these peptides showed intrinsic molecular mass values different from
those predicted in 1-integrin.
|
|
Because 1-integrin is a glycoprotein with an apparent
molecular mass of 130 kDa that can be deglycosylated to a
100-kDa core protein, we tested its capacity to associate with SL
chain. However, a mAb specific for 1-integrin
co-precipitated neither Vpre-B1, 5 nor the 35-65-kDa molecules from
the 125I-labeled pro-B cell line (Fig. 1B).
Furthermore, a mAb specific for 6-integrin (which is
associated with 1-integrin on the pro-B cell line),
proved also unable to co-precipitate Vpre-B1 and 5. Moreover, the
130-kDa spot of 1-integrin on two-dimensional gel exhibited a slightly different mobility on two-dimensional gel when
compared with the SL chain-associated p130 spot (data not shown). These
facts were taken as an indication that it was not 1-integrin but the unknown p130 protein that was capable
of association with SL chain. Five of six unknown sequences with no
sequence relationship to 1-integrin showed significant
homologies to cadherin molecules (Table I).
Cloning and DNA Sequence Analysis of p130 cDNA--
One of the
amino acid sequences obtained from the unknown, cadherin-like p130
material, IVQGDTEXRLEVVTDPTTNA from peak 37 (Fig. 1,
D and E), was long enough to design PCR primers
with which the cloning of p130 cDNA could be attempted using the
RACE technique (see "Experimental Procedures"). By repeating the
RACE-PCR with a 38B9 cell cDNA library, we were able to obtain a
full-length cDNA sequence of p130 (Fig.
2).

View larger version (99K):
[in this window]
[in a new window]
|
Fig. 2.
cDNA and deduced amino acid sequence of
mouse BILL-cadherin. The amino acid sequences determined from
lysine-C fragment are shown as *1-*5. The
potential N-glycosylation sites are shown with circles. The
putative transmembrane domain is underlined with a
bold line. The cadherin motifs and the cysteine residues
conserved in cadherin superfamily are marked with squares.
The position corresponds to HAV motif found in classic cadherins is
indicated by a hatched block. The extracellular region was
subdivided into seven cadherin domains as EC1, EC1a, EC2, EC2a, EC3,
EC4, and EC5, although EC2a seems to be a pseudo-domain because it does
not contain cadherin motifs. These sequence data are available from
GenBank/EMBL/DDBJ under the accession number D87912.
|
|
The cDNA sequence has one long open reading frame encoding 827 amino acids. This is in agreement with the finding that the deglycosylated core protein of p130 is about 100 kDa. The FastA search
of this amino acid sequence revealed a high degree of homology to the
superfamily of cadherin molecules, especially to rat LI-cadherin (90%
homology) and human HPT-1 (79% homology). At the nucleotide level, the
homology of p130 cDNA to rat LI-cadherin and human HPT-1 is 91.6 and 80.8%, respectively. The p130 sequence contains consensus cadherin
signatures such as LDRE, DXNDN, and DXD as well
as four Cys residues in a membrane-proximal region (one in EC4 and
three in premembrane domains; Fig. 2). The organization of cadherin
domains in p130 resembles nonclassic rather than classic cadherins,
because p130 lacks the "precursor segment" and is composed of five
cadherin domains and one pseudo-domain. In addition, the HAV motif,
which is conserved in EC1 of classic cadherins, and which is thought to
be important in the counterpart homotypic recognition, is replaced in
p130 by AAL, as it is in LI-cadherin and HPT-1. However, the most
striking difference from the classic cadherins is a lack of the
"catenin-binding motif" in the cytoplasmic domain. The cytoplasmic
domain of p130 consists of 18 amino acids in which, by homology search,
no significant consensus motifs are found that go beyond those for
LI-cadherin and HPT-1.
The Association of p130 with 5/Vpre-B1--
Because p130 was
identified in biochemical studies as a SL chain-associated molecule,
this interaction between p130 and 5/Vpre-B1 was probed by
co-expression of the Vpre-B1, 5, and p130 genes in a suitable cell
line, followed by co-immunoprecipitation. The myeloma cell line
X63.Ag8.653 does not express p130 or SL chain. It was first transfected
with mouse Vpre-B1 and 5 cDNAs. A stable transfectant,
X63/Vpre-B1/ 5, was further transfected with p130 cDNA
(X63/Vpre-B1/ 5/p130). Surface expression of the Vpre-B1, 5, and
p130 molecules on these stable transfectants were examined by the
flowcytometry. The results of these experiments are shown in Fig.
3.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Transfection of p130 cDNA up-regulate the
surface deposition of Vpre-B1/ 5. The
Vpre-B1/ 5 transfected myeloma line, X63/Vpre-B1/ 5, was
supertransfected with p130 cDNA. Two p130 transfectant clones,
X63/Vpre-B1/ 5/p130_ASD and X63/Vpre-B1/ 5/p130_ASI, were analyzed
by surface staining with anti- 5 (LM34) and anti-p130 (BD1B) as
compared with original Vpre-B1/ 5 transfectants
(X63/Vpre-B1/ 5). N.C., negative control with
isotype-matched antibody.
|
|
p130 is expressed on the surface of X63/Vpre-B1/ 5/p130
transfectants, and 5 is strongly expressed on these cells as well. A
small amount of 5 is detected on the surface of X63/Vpre-B1/ 5 transfectants. However, the 5 surface expression is increased by
concomitant p130 expression, so that the mean fluorescence intensities
are 4-fold higher. These results indicate that p130 expression
up-regulates 5 surface expression.
The interaction of p130 with SL chain could also be seen in
co-immunoprecipitation experiments. To test this interaction 38B9 pro-B
cells were surface iodinated, then lysed, and finally
immunoprecipitated with specific antibodies. As shown in Fig.
4A, reciprocal
co-precipitation was observed. 5-specific as well as
Vpre-B1-specific mAbs co-precipitated 130-kDa protein with 21.5-kDa
5 and 16-kDa Vpre-B1, whereas p130-specific mAb co-precipitated
21.5- and 16-kDa proteins together with 130-kDa p130. Control
immunoprecipitations with rat normal Ig did not precipitate the 130-, 21.5-, and 16-kDa bands. The identities of Vpre-B1, 5, and p130
proteins in the bands on the gels were confirmed by Western blots,
showing that the 130- and 21.5-kDa bands specifically react with
p130-specific and 5-specific mAbs, respectively (Fig.
4B).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 4.
The association of
Vpre-B1/ 5 and p130. A,
Vpre-B1/ 5 and p130 are reciprocally co-precipitated with each
antibody. 38B9 pro-B cell line was labeled with 125I and
Nonidet P-40 lysate was immunoprecipitated with rat normal-Ig,
anti- 5 (LM34), anti-Vpre-B1 (VP245), and anti-p130 (BD1B). The
precipitated proteins were analyzed on SDS-PAGE (6-15% gel).
B, the identification of co-precipitated bands. 38B9 cells
were lysed with Nonidet P-40 lysis buffer and precipitated with
anti- 5, rat normal-Ig and anti-p130 (BD1B). After the SDS-PAGE (12%
gel) and blotting to polyvinylidene difluoride membrane, proteins were
probed with biotinylated anti- 5 (rabbit polyclonal antibody)
(left panel) and biotinylated anti-p130 using the
125I-Streptavidin as a second reagent (right
panel). Note that the reciprocally co-precipitated 21.5- and 130-kDa bands were reacted specifically with anti- 5 and
anti-p130. C, the surface complex on the transfectants. The
negative control cells (X63 myeloma) and the transfected cells
(X63/Vpre-B1/ 5 and X63/Vpre-B1/ 5/p130) are the same cells as
described in the Fig. 3. The cells were labeled with 125I,
lysed with Nonidet P-40 lysis buffer, and immunoprecipitated with the
indicated antibodies. The positions of p130, 5, and Vpre-B1 are
indicated.
|
|
The ratios of p130 protein to SL chain, however, are different in the
precipitations with the different antibodies. Estimation of the
quantities of radioactivity in the bands indicates that the ratio of
5 to p130 is roughly 1:2 for the case of precipitation with
5-specific mAb, whereas it is 1:50 in the case of p130-specific mAb.
Possible interpretations for these differences will be discussed under
"Discussion."
Interaction between Vpre-B1/ 5 and p130 is also seen when the
Vpre-B1, 5, and p130 protein expressed in the transfectants are
analyzed by immunoprecipitation after surface iodination. In the
transfectants described in Fig. 3, reciprocal co-precipitation with
5-specific and p130-specific mAbs could be seen in
X63/Vpre-B1/ 5/p130 (Fig. 4C).
p130 Mediates Homotypic Adhesion without Catenin-binding
Motif--
p130 lacks the catenin-binding motif in its cytoplasmic
domain, which, in classic type cadherins, is thought to be the main functional part of the molecules mediating homotypic adhesion. To
examine any homotypic adhesion activity mediated by the p130 molecule,
we transfected the Drosophila cell line SL3 with full-length p130 cDNA, in which the expression of p130 is controlled by the metallothionein promoter. Stable transfectants were isolated, and
possible self-aggregation of the cells was examined. As shown in Fig.
5, Ca2+-dependent
self-aggregation is induced in the transfected SL3 cell line, whereas
the control cells, in which p130 expression is not induced by the
addition of CuSO4, do not show any self-aggregation. These
results indicate that p130 shows cadherin functions. It can mediate
Ca2+-dependent homotypic cell-cell adhesion
even without a classical catenin-binding motif.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 5.
p130 induces
Ca2+-dependent homotypic cell-cell
adhesion. Drosophila SL3 cells were transfected with
p130 cDNA under the metallothionein promoter. The stably
transfected cells were cultured for 2 days with (or without) 0.7 mM CuSO4 to induce (or uninduce) the expression
of p130 on membrane. The cells were then cultured with 5 mM
Ca2+ or 10 mM EGTA. The time course of
self-aggregation of the cells was monitored and counted under the
microscopy. The number of particles at time t
(Nt) divided by the number of particles at time 0 (No) are plotted versus time (min).
|
|
Expression Pattern of p130 Message--
To examine the expression
pattern of p130 on mRNA level, Northern blot analyses and
semi-quantitative RT-PCR were carried out with RNA samples obtained
from a variety of tissue and cells representing the B lineage and other
cell lineages. Northern blot analyses of tissues showed that p130
message is expressed in spleen, bone marrow, lung, testis, and, most
strongly, in the intestine (Fig.
6A). Liver, kidney, heart,
brain, skeletal muscle, and thymus did not express detectable amount of
the message. Because p130 message is not detectable, even by the PCR,
in liver our results indicate a clear difference from the expression
pattern of rat LI-cadherin (rat liver-intestine-specific cadherin)
(41).

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 6.
Expression of p130 message in cells and
tissues. (A) Northern blot analysis of p130
expression in a panel of mouse tissues and cell lines (B).
The cell lines used are pro-B (38B9, 63-12), pre-B (Ig6.3, NFS5.3),
immature B (WEHI231), mature B (A20), myeloma (X63), hybridoma (SP6),
immature T (SCFET27F), T lymphoma (EL4, B6.2.16.BU), macrophage (WEHI3,
P388D1, J774.A.1), stroma cells (PA6, ST2), and fibroblast (NIH3T3).
For the Northern blot, poly(A)+ RNA (2 µg/lane) from
various mouse tissues (A-a and A-b) and total RNA
(20 µg/lane) from various mouse cell lines (B) were size
fractionated on 1.2% agarose gel containing formaldehyde, blotted onto
nylon membranes, and subsequently hybridized with the
32P-labeled 0.2-kilobase fragment of p130 cDNA and with
5 cDNA probes (see "Experimental Procedures"). Equal loading
of RNA was confirmed by the -actin probe. Markers of RNA molecular
weight ladder (in kilobases) are indicated. C,
RT-PCR analysis on sorted mouse bone marrow and spleen cells. 3 × 103 cells of each fraction were sorted from the bone marrow
and spleen of C57BL/6 mice (5 weeks old), and the message was amplified
by RT-PCR and detected with the Southern hybridization with
32P-labeled 0.2-kilobase fragment of p130 cDNA. The
control hybridization with HPRT cDNA is also shown (see
"Experimental Procedures").
|
|
Tested with a panel of cell lines, expression of p130 message appears
restricted to precursor B cells and myeloid cells (Fig. 6B).
Pro-B and pre-B-I cell lines such as 38B9 and 63-12 express relatively
high amounts of the message, as they do the 5 message. PreB-II type
cell lines, such as NFS5.3 expressed low levels of p130 message,
whereas pre-B-II type cell line Ig6.3 did not express detectable amount
of the message. The immature B cell line, WEHI231, expressed small
amounts of the message, whereas no message was detectable in the mature
B cell line A20, the myeloma X63, and the hybridoma SP6. In addition to
B lineage cell lines, one of the macrophage lines, P388.D1, expressed
significant amount of the message, whereas more mature macrophage line,
WEHI3, did not. It should be recalled that P388.D1 has been seen to be
a line capable of myeloid as well as pre-B cell differentiation (42). This prompted an examination of p130 RNA expression in the progenitor cell lines, HAFTL-1. HAFTL-1 is a v-Ha-ras transformed fetal
liver-derived progenitor B cell clone from which pre-B cell-like (clone
14) and macrophage-like (3G4, 2B7, 1G4) subclones were isolated by induced differentiation with LPS or interleukin-4 (43). Among these
clones, the progenitor clone HAFTL-1 expressed strongly, the pre-B
subclone expressed weakly, whereas the myeloid subclones did not
express detectable amount of the message (data not shown). The T cell
lines (SCFET27F, EL4, and B6.2.16.BU), stromal cell lines (PA6 and
ST2), and fibroblast (NIH3T3) did not express detectable amounts of the
message. These results suggest that p130 message is expressed strongly
in pro-B and pre-B-I cell and less strongly in pre-B-II-type cell lines
but probably not in mature macrophage, T cell, and stromal cell lines.
To examine expression of p130 message in normal cells of bone
marrow and spleen, B-lymphocyte lineage subpopulations were purified by
differential, preparative fluorescence-activated cell sorter, and RNA
expression was examined by semi-quantitative RT-PCR (Fig.
6C). In bone marrow, B220+/c-Kit+
pro/pre-B-I cells expressed high levels of the message. Interestingly, the message was not detectable in CD25+ large and
CD25+ small pre-B-II cells but became detectable again in
IgM+/IgD immature and
IgM+/IgD+ mature B cell populations. In spleen,
B220+ and Mac-1+ cells expressed the message,
whereas CD4+ and CD8+ fractions did not. These
results suggest that the expression of p130 message in vivo
is confined to B lineage cells. The expression of p130 appears to be
biphasic during the B cell development: on in pro- and pre-B cells, off
in pre-B-II cells, and on again in immature and mature B cells.
Expression of p130 Protein--
Expression of the p130 protein was
examined with the p130-specific BD1B mAb. This mAb 1)
immunoprecipitates 130 kDa protein, 2) reacts specifically with p130
transfectants, and 3) does not react with pro/pre-B-I cells from mice
in which the p130-gene has been mutated by targeted disruption. In the
bone marrow of 5-week-old C57BL/6 mice, about 15% of
B220 cells and 40% of B220+ cells are
p130+ (Fig. 7A,
panel a). In the B220 population of cells,
most of the p130+ cells are Mac-1+ cells.
Further analysis of CD34+ early progenitors showed that the
onset of p130 expression occurs already at these earlier stages of B
lineage differentiation, i.e. in
linlo/CD34+ cells, which might represent cells
close to hematopoietic stem cells (Fig. 7A, panel
b).

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 7.
The biphasic expression of p130 protein
during the B cell development. Bone marrow (A) and
spleen cells (B) from C57BL/6 mice (4-5 weeks old) were
analyzed by the flowcytometry. A, panel a, total
bone marrow cells were stained with anti-B220 and anti-p130 (BD1B).
Panel b, the total bone marrow cells were stained with
lineage markers (FITC-labeled B220, CD3, CD4, CD8, Mac-1, Gr-1, and
Ter-119), CD34 (Cy5) and anti-p130 (biotinylated BD1 detected with
PE-Streptavidin). The four gates (1-4) are set
based on the expression level of lineage markers and CD34. The
expression level of the p130 is analyzed in each gate using the
isotype-matched mAb as a negative control. Note that
lin /CD34 and
lin /CD34+ populations do not express p130
whereas linlo/CD34+ and
lin+/CD34+ populations express p130.
Panels c and d, the expression of p130 in
pro/pre-B cells. Total bone marrow cells were stained with anti-c-Kit
(PE-labeled) (panel c) and anti-CD25 (PE-labeled)
(panel d) as well as anti-B220 (Cy5 labeled) and anti-p130
(biotinylated BD1 detected with RED613-Streptavidin). The gates
indicated are analyzed for the p130 expression. Note that
c-Kit+/B220lo pro/pre-B-I cells express p130
whereas CD25+/B220lo pre-B-II cells do not.
Panel e, the expression of p130 in immature/mature B cells.
Total bone marrow cells were stained with anti-IgM (Cy5), anti-IgD
(FITC), and anti-p130 (biotinylated BD1 detected with PE-Streptavidin).
The gates indicated are analyzed for the p130 expression. Note that
p130 is expressed most strongly in IgMhi/IgD+
population and that it is down-regulated in
IgMlo/IgD+/lo population. B, the
expression of p130 in spleen cells. Panel a, total spleen
cells were stained with anti-B220 (FITC) and anti-p130 (biotinylated
BD1 detected with PE-Streptavidin). The majority of p130+
cells are B220+. Panel b, total spleen cells
were stained with anti-CD21 (FITC), anti-CD23 (PE), and anti-p130
(biotinylated BD1 detected with RED613-Streptavidin). Note that
CD21+/CD23 /lo B cells express the highest
amount of p130.
|
|
A small numbers of cells in the B220lo population were
found to be p130+. Further dissection of this population
with c-Kit- and CD25-specific mAbs revealed that
B220lo/c-Kit+ pro/pre-B-I cells are
p130+, whereas B220lo/CD25+
pre-B-II cells are p130 (Fig. 7A, panels
c and d). This is in line with the observed down-regulation of p130 mRNA in pre-B-II-like cell lines.
However, a large part of the B220hi more mature B lineage
cells is p130+ again. The dissection of this population by
IgM- and IgD-specific mAbs into immature and mature sIg+ B
cells revealed that p130 expression is low in
IgM+/IgD immature B cells and is up-regulated
upon IgD expression (Fig. 7A, panel e).
Interestingly, the expression is again down-regulated in the
IgMlo/IgD+ population. Collectively these
results indicate that mature B cells in the bone marrow express the
highest level of p130 protein.
In the spleen, most p130+ cells are B220hi
(Fig. 7B). Among the B220hi cells, the
CD21+/CD23 /lo cells express the highest
amount of p130, with a mean fluorescent intensity that is 10 times
higher than CD21loCD23+ or
CD21+CD23+ subpopulations (Fig. 7B,
panel b). These CD21+/CD23 /lo
cells most likely are marginal zone B cells. Consistent with this
analysis is the histochemical analysis with p130-specific mAb on spleen
sections, which showed that p130+ cells were mainly located
in the marginal zone, and only scattered positive cells are in the
primary follicles (Fig. 8).
p130+ cells are almost absent from T cell rich zones in
the peri-arteriolar lymphoid sheath.

View larger version (110K):
[in this window]
[in a new window]
|
Fig. 8.
p130 is most strongly expressed in the
marginal zone. The serial cryosections of spleen from 4-week old
C57BL/6 mouse were stained with anti-IgM (A,
blue) and anti-IgD (A, brown) and
anti-p130 (B, brown, counter-stained with
Giemsa). The marginal zone (MZ), red pulp
(R), primary follicle (F), and T cell zone
(T) are indicated.
|
|
 |
DISCUSSION |
We have identified a nonclassical cadherin of 130 kDa (called
p130) that can be found noncovalently associated with SL chain in mouse
pro- and pre-B-I cells. We call it BILL-cadherin, because it is
expressed in B lineage cells, intestine, leukocytes, and liver. As far
as we know, this is the first instance that such a cadherin has been
found in B lineage cells. BILL-cadherin has characteristic
extracellular cadherin domains and lacks catenin-binding motifs in its
cytoplasmic domain, as nonclassical cadherins do. The amino acid
sequence is very similar to that of rat LI-cadherin (liver-intestine-specific cadherin; Ref. 41) and human HPT-1 (44), and,
to a lesser extent, of rabbit kidney-specific cadherin (45).
It is very possible that BILL-cadherin is the mouse homologue of rat
LI- or human HPT-1 cadherin. However, in contrast to rat LI-cadherin,
mouse BILL-cadherin message is not detected in adult mouse liver,
although B cells in mouse fetal liver do express the molecule.
The cadherin family is divided into two subgroups, classic and
nonclassic types, based on the presence or absence of a catenin-binding site in their cytoplasmic domain. About 20 classic cadherins have been
identified in a single vertebrate species and have been shown to be
involved in many phases of morphogenesis. In the nervous system, for
example, most of 20 classic cadherins show "regional" expression
and are thought to confer region-specific adhesiveness during the
neural morphogenesis and synaptic plasticity (46-48). Adhesiveness is
a Ca2+-dependent process. In homotypic adhesion
two cells of the same or of different differentiation lineages at the
same or different stage of development adhere to each other through
contacts by the same molecule, e.g. cadherin, expressed on
the two cells. Heterotypic adhesion involves one molecule,
e.g. cadherin, to a different molecule, e.g.
integrins. For example, E-cadherin on mucosal epithelial cells
was seen to interact with
E 7/ M290 7 integrin on T cells (49, 50). The sites for homotypic and for
heterotypic interactions of E-cadherin have been found to be different
(51).
Adhesion via classic cadherins induces signal transduction via catenin
family molecules that find a binding domain in the cytoplasmic domain
of the cadherins (reviewed in Ref. 52). This signal transduction is
thought to be involved in the morphogenetic changes that the cells
undergo during their differentiation. We have not yet investigated
whether BILL-cadherin is associated with some of the proteins that are
found in the complex in addition to SL chain coprecipitated from pro-B
and pre-B-I cells. Because BILL-cadherin lacks the catenin-binding
domain, it would be interesting to examine whether another component of
the complex (105- and 35-65-kDa) exerts a signaling function.
The nonclassic cadherins, which lack a catenin-binding motif, are
further divided into three subgroups, protocadherins (53), CNR (54),
and cadherins that are different from either of the two. Interestingly,
genes for protocadherins and CNRs represent an organized genomic
structure like those for immunoglobulins and T cell receptors,
suggesting the possibility of diversifying their specificities by gene
rearrangement-like mechanism (55, 56). BILL-cadherin appears to differ
from CNR and protocadherin because it has a particularly short
cytoplasmic domain. It is unclear whether nonclassic cadherins can
induce signals, and if they do by which molecular modes, although CNR
molecules are associated with Fyn tyrosine kinase in their cytoplasmic
domains (57). These molecules are also expressed regionally in various
tissues including brain and thought to be involved in "sorting out"
of the cells (47). However, it is clear that rat LI-cadherin (58) and
BILL-cadherin (this study) are able to exert
Ca2+-dependent homotypic adhesion. Hence,
BILL-cadherin could be involved in the "sorting" or "homing" of
cells during the B cell development in primary lymphoid organs such as
fetal liver and bone marrow as well as during immune responses of
mature B cells in secondary lymphoid organs.
Our RT-PCR and flow cytometric analyses show that BILL-cadherin is
expressed in two phases during B cell development in the bone marrow.
Lin CD34 and
lin CD34+ hematopoietic stem cells, which
according to Nakauchi and co-workers (59) are long term and short term
repopulating cells, both do not express BILL-cadherin. Expression
appears to begin in linlo/CD34+ cells (Fig.
7A, panel b). The onset of the expression was
also determined to occur in B220lo/HSA cells
that correspond to fraction A in Hardy's definition of bone marrow
cells related to B lineage development (60). BILL-cadherin is then
up-regulated in pro- and pre-B-I cells, down-regulated in large and
small pre-B-II cells, and up-regulated again in immature and mature B cells.
Before the SL chain forms the pre-B cell receptor with µ heavy chain
on large pre-B-II cells during B cell development (17), it is already
expressed on the surface of µ-chain nonexpressing pro-B and pre-B-I
cells (23). Within the complex of 130-, 105-, and 35-65-kDa
glycoprotein components, SL chain is associated in the pro- and pre-B-I
cells. p130, a new nonclassic cadherin, may be the component to which
SL chain binds. Recent crystallographic studies of E-cadherin have
revealed a remarkable structural similarity with immunoglobulin
domains, visible in the organization of the -strand structure
(61-63). The N-terminal domain of E-cadherin, which shows this
structural homology with Ig domain, is the one that is involved in the
Ca2+-induced rigidification and dimerization and that this
is thought to be the basis for homotypic adhesion mediated by cadherins
(64). SL chain consists of a light chain constant region-like
domain of the 5 protein, a J -like 7 strands of a V-like domain
also contributed by the 5 protein, to which the Vpre-B1 protein
associates in an Ig domain-like fashion (65, 66). Therefore, SL chain on BILL-cadherin could interact with each other in an Ig domain/Ig domain-like way.
Several experimental findings presented in this paper favor the
interpretation that such an interaction between BILL-cadherin and SL
chain exists. SL chain ( 5)-specific mAb co-precipitate BILL-cadherin
from pro-B and pre-B-I cell lines, as well as from myeloma cells
co-transfected with the genes encoding SL chain and BILL-cadherin. The
BILL-cadherin/SL-chain complex is expressed on pro-B cells of
RAG2 / mice but not on pro-B and pre-B-I cells of
5 / mice. Co-precipitation of the BILL-cadherin and
SL chain-containing complex from myeloma cells transfected with the
corresponding genes is almost equimolar with 5-specific mAbs but not
with BILL-cadherin specific mAb. The latter mAb might recognize a
determinant that could be partially covered or otherwise nonavailable
in the complexes. However, none of our experiments exclude the
possibility that the interaction between BILL-cadherin and SL chain is
indirect, within a complex of other proteins, especially the ones
co-precipitated as 105 and 35-65-kDa bands.
Expression of BILL-cadherin is up-regulated in pro-B and pre-B-I cells,
which is in parallel with the expression of SL chain. Interestingly,
expression is down-regulated again at the stage when c-kit and CD43 are
down-regulated, and CD25 is up-regulated, i.e. at the
transition from pre-B-I to large pre-B-II cells. At this transition the
pre-B cell receptor composed of µ heavy chain and SL chains appear on
the surface, and this leads to a subsequent down-regulation of SL chain
expression. In principle, the parallel patterns of expression of
BILL-cadherin and SL chain in precursor B cells would permit a mutual
association throughout these cellular stages. In pre-B-II cells µ heavy chains would replace BILL-cadherin in a complex with SL chain and
terminate the expression of SL chain. It will be interesting to see
whether the concerted expression of BILL-cadherin and SL chain is a
consequence of shared gene expression controls.
BILL-cadherin expression is up-regulated again in later stages of B
cell differentiation. Newly emerging mature B cells begin to express
BILL-cadherin. In the spleen, the
B220+/CD21+/CD23lo/ population,
which corresponds to the marginal zone B cells (67), expresses the
highest level of BILL-cadherin. This observation is consistent with the
histological staining of spleen sections with BILL-cadherin specific
mAb, which show the marginal zone as the most strongly stained
structure. Some of the B cells in the marginal zone have been found to
belong to the B1 lineage of B cell development and to be activated,
possibly by cross-reactive autoantigens (16). Further analyses are
aimed at identifying the antigen-recognizing repertoire of the
p130hi B cells in spleen. If they appear cross-reactive and
autoreactive, then high level p130 expression might be used as an
analytical tool for B1 cell identification.
In conclusion the biphasic expression profile of BILL-cadherin suggests
at least two different functions of the molecule during B cell
development and responses. These functions are now being explored.
 |
ACKNOWLEDGEMENTS |
We thank Dr. William Lane and David Avila for
the intensive analysis of peptide sequencing, as well as Joachim Scherf
for excellent technical assistance.
 |
FOOTNOTES |
*
This work was conducted at the Basel Institute for
Immunology, which was founded and is supported by Hoffman-La Roche
Ltd., Basel, Switzerland.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) D87912.
§
To whom correspondence should be addressed. Present address: Dept.
of Immunology, National Institute of Infectious Diseases, Tokyo
162-8640, Japan. Tel.: 81-3-5285-1111; Fax: 81-3-5285-1156; E-mail:
ohnishik@nih.go.jp.
Published, JBC Papers in Press, July 20, 2000, DOI 10.1074/jbc.M005901200
 |
ABBREVIATIONS |
The abbreviations used are:
SL chain, surrogate
light chain;
RT, reverse transcription;
PCR, polymerase chain reaction;
NEPHGE, nonequilibrium isoelectric focusing;
PAGE, polyacrylamide gel
electrophoresis;
MALD-MS, matrix-assisted laser dissorption mass
spectrography;
BILL-cadherin, B cell, intestine, liver, and leukocyte
cadherin;
mAb, monoclonal antibody;
RACE, rapid amplification of
cDNA ends;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
HPLC, high pressure liquid chromatography;
HPRT, hypoxanthine
phosphoribosyltransferase;
HPT-1, human intestinal peptide transporter
1;
CNR, cadherin-related neuronal receptor;
FITC, fluorescein
isothiocyanate;
PE, phycoerythrin;
IL, interleukin.
 |
REFERENCES |
| 1.
|
Tonegawa, S.
(1983)
Nature
302,
575-581
|
| 2.
|
Melchers, F.,
Rolink, A.,
Grawunder, U.,
Winkler, T. H.,
Karasuyama, H.,
Ghia, P.,
and Andersson, J.
(1995)
Curr. Opin. Immunol.
7,
214-227
|
| 3.
|
Rolink, A.,
and Melchers, F.
(1991)
Cell
66,
1081-1094
|
| 4.
|
Osmond, D. G.
(1990)
Semin. Immunol.
2,
173-180
|
| 5.
|
Kincade, P. W.
(1991)
Semin. Immunol.
3,
379-390
|
| 6.
|
Ogawa, M.,
Sugawara, S.,
Kunisada, T.,
Sudo, T.,
Hayashi, S.,
Nishikawa, S.,
and Kodama, H.
(1998)
Exp. Hematol.
26,
478-488
|
| 7.
|
Sudo, T.,
Ito, M.,
Ogawa, Y.,
Iizuka, M.,
Kodama, H.,
Kunisada, T.,
Hayashi, S.,
Ogawa, M.,
Sakai, K.,
and Nishikawa, S.
(1989)
J. Exp. Med.
170,
333-338
|
| 8.
|
Nishikawa, S.,
Ogawa, M.,
Kunisada, T.,
and Kodama, H.
(1988)
Eur. J. Immunol.
18,
1767-1771
|
| 9.
|
Rolink, A.,
Karasuyama, H.,
Grawunder, U.,
Haasner, D.,
Kudo, A.,
and Melchers, F.
(1993)
Eur. J. Immunol.
23,
1284-1288
|
| 10.
|
von Freeden-Jeffry, U.,
Vieira, P.,
Lucian, L. A.,
McNeil, T.,
Burdach, S. E.,
and Murray, R.
(1995)
J. Exp. Med.
181,
1519-1526
|
| 11.
|
Kincade, P. W.,
He, Q.,
Ishihara, K.,
Miyake, K.,
Lesley, J.,
and Hyman, R.
(1993)
Curr. Top. Microbiol. Immunol.
184,
215-222
|
| 12.
|
Jacobsen, K.,
and Osmond, D. G.
(1990)
Eur. J. Immunol.
20,
2395-2404
|
| 13.
|
D'Apuzzo, M.,
Rolink, A.,
Loetscher, M.,
Hoxie, J. A.,
Clark-Lewis, I.,
Melchers, F.,
Baggiolini, M.,
and Moser, B.
(1997)
Eur. J. Immunol.
27,
1788-1793
|
| 14.
|
Stevens, S. K.,
Weissman, I. L.,
and Butcher, E. C.
(1982)
J. Immunol.
128,
844-851
|
| 15.
|
Sprent, J.
(1973)
Cell Immunol.
7,
10-39
|
| 16.
|
Chen, X.,
Martin, F.,
Forbush, K. A.,
Perlmutter, R. M.,
and Kearney, J. F.
(1997)
Int. Immunol.
9,
27-41
|
| 17.
|
Melchers, F.,
Karasuyama, H.,
Haasner, D.,
Bauer, S.,
Kudo, A.,
Sakaguchi, N.,
Jameson, B.,
and Rolink, A.
(1993)
Immunol. Today
14,
60-68
|
| 18.
|
Kitamura, D.,
Kudo, A.,
Schaal, S.,
Muller, W.,
Melchers, F.,
and Rajewsky, K.
(1992)
Cell
69,
823-831
|
| 19.
|
Loffert, D.,
Ehlich, A.,
Muller, W.,
and Rajewsky, K.
(1996)
Immunity
4,
133-144
|
| 20.
|
Melchers, F.,
ten Boekel, E.,
Yamagami, T.,
Andersson, J.,
and Rolink, A.
(1999)
Semin. Immunol.
11,
307-317
|
| 21.
|
Winkler, T. H.,
Rolink, A.,
Melchers, F.,
and Karasuyama, H.
(1995)
Eur. J. Immunol.
25,
446-450
|
| 22.
|
Karasuyama, H.,
Rolink, A.,
Shinkai, Y.,
Young, F.,
Alt, F. W.,
and Melchers, F.
(1994)
Cell
77,
133-143
|
| 23.
|
Karasuyama, H.,
Rolink, A.,
and Melchers, F.
(1993)
J. Exp. Med.
178,
469-478
|
| 24.
|
Shinjo, F.,
Hardy, R. R.,
and Jongstra, J.
(1994)
Int. Immunol.
6,
393-399
|
| 25.
|
Sanz, E.,
and de la Hera, A.
(1996)
J. Exp. Med.
183,
2693-2698
|
| 26.
|
Takemori, T.,
Miyazoe, I.,
Shirasawa, T.,
Taniguchi, M.,
and Graf, T.
(1987)
EMBO J.
6,
951-956
|
| 27.
|
Saint-Ruf, C.,
Ungewiss, K.,
Groettrup, M.,
Bruno, | |